CDC23: A Potential Drug Target and Biomarker for Cell Division Cycle 23
CDC23: A Potential Drug Target and Biomarker for Cell Division Cycle 23
Cancer is a leading cause of morbidity and mortality worldwide, with over 20 million new cases and 5.5 million deaths in 2020, according to the World Health Organization (WHO). The primary cause of cancer is cell division cycle (CDC) errors, which lead to the uncontrolled growth and proliferation of cells. One of the most significant errors in the CDC is cell division cycle 23 (CDC23), which has been implicated in the development and progression of many types of cancer. Therefore, identifying potential drug targets and biomarkers for CDC23 is of great clinical importance.
In this article, we will discuss CDC23, its function, and its potential as a drug target and biomarker. We will also review the current research on CDC23 and its potential clinical applications.
CDC23: A Complex Cellular Process
CDC23 is a critical enzyme in the DNA replication process that plays a central role in cell division cycle. It is a protein that adds a phosphate group to the active site of the enzyme DNA polymerase, which is responsible for replicating the DNA in the cell. CDC23 is essential for the efficient and accurate replication of DNA during the cell division cycle.
CDC23 has four distinct subunits, A, B, C, and D, that work together to add the phosphate group to the active site of DNA polymerase. The subunit A is the catalytic subunit, while subunits B, C, and D interact with the substrate and regulate the addition of the phosphate group.
CDC23 is also involved in other cellular processes, including cell signaling, cell adhesion, and cell migration. It has been shown to play a role in the regulation of cell cycle progression, apoptosis, and autophagy.
Potential Drug Targets and Biomarkers
CDC23 is a drug target of great interest because of its involvement in the development and progression of many types of cancer. Several studies have identified potential inhibitors for CDC23 that could be used in cancer treatment.
One of the most promising compounds is called RG7843, which is a small molecule inhibitor of CDC23. RG7843 has been shown to inhibit the growth of various cancer cell lines, including breast, lung, and colorectal cancer.
Another compound that has potential as a drug target for CDC23 is called SCL-3, which is a small molecule inhibitor of the protein kinase PDK4. SCL-3 has been shown to inhibit the activity of PDK4, which is a key regulator of CDC23, in cancer cells.
Biomarkers
CDC23 is also a potential biomarker for cancer. The expression of CDC23 has been shown to be elevated in various types of cancer, including breast, lung, and colorectal cancer. This suggests that CDC23 may be a useful biomarker for cancer diagnosis and monitoring.
CDC23 is also involved in the regulation of cell cycle progression, which is a critical step in the development and progression of cancer. Therefore, measuring the level of CDC23 expression in cancer cells could be a useful biomarker for the assessment of disease stage and response to therapy.
Conclusion
In conclusion, CDC23 is a complex cellular process that is critical for the regulation of cell division cycle. Its role in the development and progression of cancer makes it an attractive target for drug development. The identification of potential inhibitors for CDC23, such as RG7843 and SCL-3, is an promising sign for the future of cancer treatment. Additionally, the measurement of CDC23 expression in cancer cells could be a useful biomarker for disease diagnosis and monitoring. Further research is needed to
Protein Name: Cell Division Cycle 23
Functions: Component of the anaphase promoting complex/cyclosome (APC/C), a cell cycle-regulated E3 ubiquitin ligase that controls progression through mitosis and the G1 phase of the cell cycle. The APC/C complex acts by mediating ubiquitination and subsequent degradation of target proteins: it mainly mediates the formation of 'Lys-11'-linked polyubiquitin chains and, to a lower extent, the formation of 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains
The "CDC23 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDC23 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18 | CDK19 | CDK2 | CDK20 | CDK2AP1 | CDK2AP2 | CDK2AP2P2 | CDK2AP2P3 | CDK3 | CDK4 | CDK5 | CDK5R1 | CDK5R2 | CDK5RAP1 | CDK5RAP2 | CDK5RAP3 | CDK6 | CDK6-AS1
